The number of lung cancer cases in people who have never smoked is increasing. The disease is different from lung cancer ...

ASCO Data Shows New Therapy Extends Survival in Small Cell Lung Cancer. Here's what you need to know about the new ...

Dr. Suresh Ramalingam discusses how Tagrisso has ushered in a new era of care for patients with advanced EGFR+ non-small cell ...

Patients with stage II and IIIB non-small cell lung cancer (NSCLC) with an EGFR mutation had better outcomes when treated ...

Findings from HERTHENA-Lung02 showed that the key secondary endpoint of overall survival did not meet statistical significance.

The BLA seeking accelerated approval for patritumab deruxtecan in previously treated, locally advanced EGFR-mutated NSCLC in ...

Patritumab deruxtecan was unable to significantly improve overall survival in patients with locally advanced or metastatic ...

SMMT's HARMONi trial shows PFS benefits for ivonescimab in EGFR-mutant NSCLC, but lack of proven overall survival raises ...

The MHRA has approved aumolertinib for adult patients with non-small cell lung cancer (NSCLC), following a groundbreaking ...

Increased activity in a specific biological pathway may explain why many patients with a deadly form of skin cancer do not ...

Dana-Farber Cancer Institute investigators launch a first-of-its kind study to use a novel blood test to identify people who ...